A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder
(2021)
Journal Article
Challapalli, A., Masson, S., White, P., Dailami, N., Pearson, S., Rowe, E., …Bahl, A. (2021). A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder. Clinical Genitourinary Cancer, 19(4), P325-332. https://doi.org/10.1016/j.clgc.2021.02.001
Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal. We evaluated the efficacy, safety, and tolerability of cisplatin plus caba... Read More about A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.